Record dealmaking announcements despite some challenges
This record start to the year has not been without its challenges. Seventy-six percent of executives highlighted they have either failed to complete or canceled a deal in the last year, motivated by competition or valuation issues.
One of the contributing factors has been the re-emergence of private equity (PE). The current M&A cycle that started in 2013 has been dominated by corporate acquirers. Over the period 2013–16, corporates have accounted for, on average, 98% of the M&A market by value. This tide is turning, with 77% of executives expecting to see even more competition for assets in the next year. Of those executives expecting more competition, 66% expect that competition to come from PE. This trend began to accelerate in 2017 when PE accounted for 6% of the M&A market (in deal value). PE continues to have an appetite for non-core assets from big pharma and medtech, accounting for 3% of the M&A market in the first quarter of this year.
Competitive bid processes are not the only challenges boardrooms need to address. Forty-six percent of executives believe political uncertainty is the greatest near-term risk to the growth of their business. Drug prices continue to be on the political agenda and often in the headlines; however, the continued rise of nationalism and protectionism does not seem to be discouraging companies from cross-border M&A. Thirty-four percent of executives are expecting an increase in cross-border dealmaking over the next 12 months.
Confidence in capital markets continues
Our recent paper on life sciences M&A, 2018 M&A Firepower Report: Life Sciences Deals and Data, highlighted how buoyant capital markets have been for small and mid-sized biopharmas and medtechs, and the potential return of megadeals. The confidence in financial markets continues, with all financial indicators in our survey remaining stable or improving. The proposed tie-up between Takeda and Shire would be the largest deal since the megadeals in 2009 (Pfizer and Wyeth merger), 2013 (Abbott and AbbVie separation) and 2015 (Allergan and Actavis merger).
Executives remain confident about dealmaking over the next 12 months, with 66% expecting the M&A market to improve. A major driver for this centers on the need for life sciences companies to mitigate the next patent cliff and, consequently, transform their portfolios by both buying and selling assets. Seventy-four percent of executives see portfolio transformation as the most prominent boardroom issue.
Making better-informed portfolio decisions in today's data-driven era
Analytics, artificial intelligence and real-time data gathering are allowing companies to make better-informed decisions about their portfolio. Seventy-six percent of executives say the main result of their portfolio review was divesting an asset identified as underperforming or at risk for disruption.
In our just-published paper, Progressions 2018: Life Sciences 4.0 — Securing value through data-driven platforms, we discuss the capabilities life sciences companies need to succeed in today's data-driven era. Our analysis shows that to avoid disruption from new entrants, life sciences companies must form partnerships to boost their patient engagement, personalization and data skills. Partnerships formed thus far are focused on the creation or enhancement of products and services, or to collect and structure real-world data.